Stakeholder Forum 2012
Start Date 30/05/2012Over 150 people attended IMI's annual Stakeholder Forum at the Husa President Park Hotel in Brussels, Belgium on Wednesday 30 May 2012.
Videos of the event can be viewed on IMI's YouTube Channel
The event featured:
- presentations on IMI project successes
- an overview of IMI’s recently-launched projects
- an update on IMI’s efforts to simplify procedures
- a debate on IMI’s impact on the pharmaceutical research and development (R&D) landscape
- workshops on the following topics from current and future IMI Calls for proposals:
- antimicrobial resistance - the final Call text is now available via the 6th Call section
- vaccines - a draft outline of the indicative Call text is now available on the Future Topics page
- effectiveness research
- networking opportunities
Presentations
Plenary Session
Welcome and introduction
Michel Goldman, Executive Director, IMI
eTOX – Data integration for in silico toxicity prediction
Gerhard Ecker, University of Vienna
Ferran Sanz, IMIM - Universitat Pompeu Fabra
Open PHACTS – the Open Pharmacological Concepts Triple Store
Gerhard Ecker, University of Vienna
Bryn Williams-Jones, Connected Discovery Ltd
Patient involvement in the PROactive project
Pim De Boer, Netherlands Asthma Foundation
IMI Education and Training: www.on-course.eu
Ghazaleh Gouya, Medical University Vienna
Introduction to IMI’s newest projects
Michel Goldman, Executive Director, IMI
Introduction to EUPATI
Nicola Bedlington, European Patients’ Forum
IMI’s simplified procedures
Nathalie Seigneuret, Senior Scientific Project Manager, IMI
Ana Padrão, IT Manager, IMI
Magali Poinot, Legal Manager, IMI
Workshop: Combating Antibiotic Resistance
Introduction
Michel Goldman, Executive Director, IMI
Combating Antibiotic Resistance: New Drugs 4 Bad Bugs (ND4BB)
David Payne, GlaxoSmithKline
IMI’s 6th Call for proposals - Procedures & Practicalities
Nathalie Seigneuret, Scientific Project Manager, IMI
Maria Teresa De Magistris, Principal Scientific Manager, IMI
Workshop: Vaccines & Effectiveness research
Introduction
Ann Martin, Principal Scientific Manager, IMI
Fatiha Sadallah, Principal Scientific Manager, IMI
Building a sustainable framework for rapid assessment of vaccination benefit/risk in Europe
Vincent Bauchau, GSK Biologicals
Incorporating relative effectiveness research into development strategies
Chris Chinn, GlaxoSmithKline, European Pharmaceuticals